Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

Perspective from Sangeeta Kashyap, MD Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the ...

A new study led by Weill Cornell Medicine researchers reveals that tirzepatide (Mounjaro, Zepbound) helps people lose significantly more weight than semaglutide (Wegovy). The difference is ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

If tirzepatide can’t be accessed, semaglutide is still a good choice because 15% weight loss, particularly at the population level, is enormous. “Ten years ago, if someone had told you semaglutide was ...